Evotec SE announced that its biologics segment expanded a strategic partnership with Sandoz to provide biosimilars to the pharma company. Under the agreement, Evotec Biologics will receive appropriate remuneration following early scientific validation. Further funding will be tied to achieving development milestones from 2025. The expanded partnership solidifies the company’s commitment to providing a long-term…
Evotec joins list of recent cyberattack targets in pharma
Evotec SE (Nasdaq:EVO), the German biotechnology company, recently succumbed to a cyberattack. Its Nasdaq shares appeared to be unaffected by the revelation, which described a IT network intrusion occurring on April 6. In a communiqué, the company said it preemptively shut down its IT systems as a result of the attack, disconnecting them from the…